Chongqing Zhifei Biological Products Co (300122) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 was ¥2.15 billion, down 8.64% year-over-year.

• Net loss attributable to shareholders was ¥388 million, a decline of 18.79% year-over-year.

• The company continues to focus on core business and innovation, leveraging multiple R&D and production bases.

Financial highlights

• Operating income decreased to ¥2.15 billion from ¥2.35 billion year-over-year.

• Net loss widened to ¥388 million from ¥327 million year-over-year.

• Basic and diluted EPS both at -0.1622, down 18.74% year-over-year.

• Operating cash flow was ¥278 million, down 16.07% year-over-year.

• Total assets at quarter-end were ¥29.09 billion, down 8.28% from year-end 2025.

Outlook and guidance

• VAT rate on products increased from 3% to 13% starting January 2026, expected to impact revenue and profit for 2026 and beyond.

• The company aims to strengthen competitiveness and foster new growth drivers through innovation and strategic layout.